trending Market Intelligence /marketintelligence/en/news-insights/trending/wLotrLT8rpBc1h7c_eLByQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

AFT Pharmaceuticals painkiller meets main goal in phase 3 trial

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


AFT Pharmaceuticals painkiller meets main goal in phase 3 trial

AFT Pharmaceuticals Ltd. said the phase 3 trial for the intravenous form of its Maxigesic painkiller met its main goal, showing that the drug provided superior pain relief compared to paracetamol, ibuprofen or placebo.

Results indicated a highly statistically significant difference between treatment groups in the primary endpoint for the improvement in sum of the pain intensity difference scores for Maxigesic in comparison with all other treatment groups.

The intravenous form of Maxigesic is a combination of 1000 milligrams of paracetamol plus 300mg of ibuprofen. It has been developed as a line extension to Maxigesic tablets primarily for postoperative usage in hospitals where patients cannot take oral medicine.

In May, the European Medicines Agency approved the Maxigesic painkiller for sale in nine additional EU member countries.